wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 20. no 4. December 2015  

 Review articles
Application of m-TOR inhibitors in the selected dermatologic lesions
Beata Imko-Walczuk

Sirolimus, also known as rapamycin, and everolimus are new drugs belonging
to the group of pharmaceuticals called m-tor inhibitors, which
have been used in transplantology as immunosuppressive drugs. M-tor
pathway, also known as m-tor kinase, plays an important role in cell cycle
regulation. M-tor pathway activation is involved in pathogenesis of some
diseases, including cancer diseases. Organ transplant receivers who are at
an increased risk of developing cancer constitute a special group of patients
for whom rapamycin is recommended for use in cancer treatment.
In dermatology, sirolimus and everolimus have been used in treatment of
tuberous sclerosis complex (TSC) and psoriasis. In the tuberous sclerosis
treatment, rapamycin became a drug of choice, particularly among patients
with TSC who need a kidney transplantation. Until now sirolimus
or everolimus have not been tested as a monotherapy in the psoriasis
treatment. However, m-tor inhibitors have been used in an associative
treatment with cyclosporine, which prevents the increase of nephrotoxicicity
by using lower doses of cyclosporine. Currently there are more and
more indications of using rapamycin in treatment of some other diseases
such as skin cancer, kidney cancer, lymphoma or leukaemia.

keywords: sirolimus, ewerolimus, szlak m-tor, terapia przeciwnowotworowa, łuszczyca, stwardnienie guzowate,sirolimus, everolimus, m-tor pathway, anticancer therapy, psoriasis, tuberous sclerosis complex

pages: from 231 to 235

estimated time of download (128 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.